Key result
Fibrillin-1 mutations and its derived hormone asprosin contribute to adipose tissue dysfunction and metabolic syndrome through impaired adipogenesis and altered glucose and insulin signaling.
Why the study?
Understanding the dynamic role of fibrillin-1 in adipose tissue and circulating asprosin can provide novel mechanistic insights into how fibrillin-1 contributes to metabolic syndrome.
Understanding the roles of fibrillin-1 and asprosin in adipose tissue and metabolism may provide novel mechanistic insights and potential management strategies for metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Does not support practice changes in metabolic syndrome; leaves open targeted research on adipose signaling pathways.
The extracellular matrix microenvironment of adipose tissue is of critical importance for the differentiation, remodeling and function of adipocytes. Fibrillin-1 is one of the main components of microfibrils and a key player in this process. Furin processing of profibrillin-1 results in mature fibrillin-1 and releases the C-terminal propeptide as a circulating hunger hormone, asprosin. Mutations in the fibrillin-1 gene lead to adipose tissue dysfunction and causes Marfan syndrome, marfanoid progeroid lipodystrophy syndrome, and neonatal progeroid syndrome. Increased TGF-β signaling, altered mechanical properties and impaired adipogenesis are potential causes of adipose tissue dysfunction, mediated through deficient microfibrils. Circulating asprosin on the other hand is secreted primarily by white adipose tissue under fasting conditions and in obesity. It increases hepatic glucose production and drives insulin secretion and appetite stimulation through inter-organ cross talk. This review discusses the metabolic consequences of fibrillin-1 and fibrillin-1-derived asprosin in pathological conditions. Understanding the dynamic role of fibrillin-1 in the adipose tissue milieu and of circulating asprosin in the body can provide novel mechanistic insights into how fibrillin-1 may contribute to metabolic syndrome. This could lead to new management regimens of patients with metabolic disease.
No takes yet. Share an insight, caveat, or question.
Muthu et al. (2020) conducted a review in Metabolic disorders. Fibrillin-1 and asprosin was evaluated. Fibrillin-1 mutations and its derived hormone asprosin contribute to adipose tissue dysfunction and metabolic syndrome through impaired adipogenesis and altered glucose and insulin signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: